Inflammatory Bowel Disease in the Elderly

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry


Inflammatory bowel disease (IBD) embraces two diseases, Crohn’s disease (CD) and ulcerative colitis (UC), which are immunologically mediated, chronic, relapsing and inflammatory conditions of unknown aetiology. In the elderly, there are two groups, elderly with onset of IBD at a later age (late onset) and, the other, elderly with a long-standing history of IBD with an initial diagnosis at a younger age. Late-onset CD has been variably defined ranging from 40 to >65 years of age. The review summarises the two diseases, Crohn’s and ulcerative colitis, with the main focus on the age of onset.


Crohn’s disease (CD) Ulcerative colitis Inflammatory bowel disease Late-onset CD Late-onset ulcerative colitis 


  1. 1.
    Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nature Clin Pract Gastroenterol Hepatol. 2006;(3):390–407.CrossRefGoogle Scholar
  2. 2.
    Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Da Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20(28):9458–67.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of inflammatory bowel disease, with time, based on systematic review. Gastroenterol. 2012;142:46–54.CrossRefGoogle Scholar
  5. 5.
    Burisch J. Crohn’s disease and ulcerative colitis. Occurrence course and prognosis during the first year of disease in a European population-based inception cohort. Dan Med J. 2014;61(1):B4778.PubMedGoogle Scholar
  6. 6.
    CCFA. Inflammatory bowel disease and older adults. retrieved on 9 October 2014.
  7. 7.
    Sung MK, Park MY. Nutritional modulators of ulcerative colitis: Clinical efficacies and mechanistic view. World J Gastroenterol. 2013;19(7):994–1004.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Karlinger K, Gyorke T, Mako E, Mestr A, Tarjan Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol. 2000;35(3):154–67.CrossRefPubMedGoogle Scholar
  9. 9.
    Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993 incidence, prevalence and survival. Gut. 2000;46:336–343.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gisbert JP, Chaparro M. Inflammatory bowel disease in the elderly. Aliment Pharmcol Ther. 2014;39(5):459–47.CrossRefGoogle Scholar
  11. 11.
    Sandler RS, Golden AL. Epidemiology of Crohn’s disease. J Clin Gastroenterol. 1986;8(2):160–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Jones HW, Hoare A. Does ulcerative colitis behave differently in the elderly? Age Aging. 1988;17:410–414.CrossRefGoogle Scholar
  13. 13.
    Robertson DJ, Grimm IS. Inflammatory bowel disease in the elderly. Gastroenterol Clin. 2001;30:409–426.CrossRefGoogle Scholar
  14. 14.
    Young-Fadok TM, Wolff BG. Inflammatory Bowel Disease in the Elderly. Principles and Pract Geriatr Surg. 2001;pp 609–619.Google Scholar
  15. 15.
    del Val JH. Old-age inflammatory bowel disease onset: A different problem? World J Gastroenterol. 2011;17(22):2734–2739.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Grimm IS, Friedman LS. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am. 1990;19:361–389.PubMedGoogle Scholar
  17. 17.
    Riegler G, Tatraglione MT, Carrutu R, D’Inca R, Valpiani D, Russo MI, et al. Age-related clinical severity at diagnosis in 1,705 patients with ulcerative colitis: a study by GISC (Italian Colon Rectum Study Group) Dig Dis Sci. 2000;45:462–465.CrossRefPubMedGoogle Scholar
  18. 18.
    Triantafillidis JK, Emmanouilidis A, Nicholas D, Ifantis T, Cheracakis P, Merika EG, et al. Crohn’s disease in the elderly: clinical features and long-term outcome of 19 Greek patients. Dig Liver Dis. 2000;32:498–503.CrossRefPubMedGoogle Scholar
  19. 19.
    Roberts PL, Schoetz DJ, Pricolo R, Veidenheimer MC. Clinical course of Crohn’s disease in older patients. A retrospective study. Dis Colon Rectum. 1990;33(6):458–462.CrossRefPubMedGoogle Scholar
  20. 20.
    Eisen GM, Schutz SM, Washington MK, Burton CS, Sidhu-Malk N, Wilson AP. Atypical presentation of inflammatory bowel disease in the elderly. Am J Gastrenterol. 1993;88:2098–2101.Google Scholar
  21. 21.
    Walmsley RS, Gillen CD, Allan RN. Prognosis and management of Crohn’s disease in the over 55 age group. Postgrad Med J 1997;73(858):225–229.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Levin A, Shibolet O. Infliximab in ulcerative colitis. Biologics. 2008;2(3):379–388.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Satsangi J, Silverberg MS, Vermeirre S, Colombel JF. The Montreal classification of inflammatory bowel disease controversies, consensus and implications. Gut 2006;55:749–753.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Angelcucci E, Cocco A, Latella G, Caprilli R. Clinical course of late-onset Crohn’s disease. Inflamm Bowel Dis 2009;15:1290–1292.CrossRefGoogle Scholar
  25. 25.
    Walker MA, Pennington CR, Pringle R. Crohn’s disease in the elderly. Br Med J Clin Res Edu. 1985:291:1725–1726.CrossRefGoogle Scholar
  26. 26.
    Lockhart-Mummery HE. Crohn’s disease of the large bowel. Br J Surg 1972;59;823.CrossRefPubMedGoogle Scholar
  27. 27.
    Hadithi M, Cazemier M, Meijer GA, Bioenema E, Felt Bersma RJ, Mulder C, et al. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastrroenterol. 2008;14(20):3183–3167.CrossRefGoogle Scholar
  28. 28.
    Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations of inflammatory bowel disease. World J Gasteroenterol. 2005;11:7227.CrossRefGoogle Scholar
  29. 29.
    Softley A, Mren J, Clamp SE, Bouchier IA, Watkinson G, de Dombal FT, et al. Inflammatory bowel disease in the elderly patients. Scand J Gastroenterol. Suppl 1988;144:27–30.PubMedGoogle Scholar
  30. 30.
    Greth J, Torok HP, Koenig A, Folwaczny C. Comparison of inflammatory bowel disease at younger and older age. Eur J Med Res. 2004;9:552–554.PubMedGoogle Scholar
  31. 31.
    Picco MF, Cangemi JR. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am. 2009;38:447–462.CrossRefPubMedGoogle Scholar
  32. 32.
    Shepherd NA. Pathological mimics of chronic inflammatory bowel disease. J Clin Pathol 1991;44:726–733.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Berner Y, Vigder C, Stern M, Feldman J. Inflammatory bowel diseases in the elderly. Harefuah. 2003;142(3):188–92PubMedGoogle Scholar
  34. 34.
    Greenwald DA, Brandt LJ. Inflammatory Bowel Disease After Age 60. Curr Treat Options Gastroenterol. 2003;6(3):2130225.CrossRefGoogle Scholar
  35. 35.
    Van Rosendaal GM, Andersen MA. Segmental Colitis complicating diverticular disease. Can J Gastroenterol. 1996;10:361–364.CrossRefPubMedGoogle Scholar
  36. 36.
    Makapugay LM, Dean PJ. Diverticular disease – associated chronic colitis. Am J Surg Pathol. 1996;20:94–102.CrossRefPubMedGoogle Scholar
  37. 37.
    Harper PC, McAuliffe T, Beeken WL. Crohn’s disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. Arch Intern Med. 1986;146:753–755.CrossRefPubMedGoogle Scholar
  38. 38.
    Komblath A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practical Parameters Committee. Am J Gastroenterol. 1997;92:204–211.Google Scholar
  39. 39.
    Van Assche G, Dignass A, Reinisch W, Jannekevan Wonde C, Sturm A, DeVos M, et al, The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease. Special situations. J Crohns Colitis. 2010;4:63–101.CrossRefPubMedGoogle Scholar
  40. 40.
    Katz S, Surawicz C, Pardi DS. Management of the elderly patients with inflammatory disease: practical considerations. Inflamm Bowel Dis. 2013;19(10):2257–72.CrossRefPubMedGoogle Scholar
  41. 41.
    Katz S, Feldstein R. Inflammatory Bowel Disease of the Elderly. A wake up call. Gastroenerol Hepatol 2008;4(5):337–347.Google Scholar
  42. 42.
    Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidenced-based Consensus on the diagnosis and management of Crohn’s disease. Special situations. J Crohns Colitis. 2010;4:28–62.CrossRefPubMedGoogle Scholar
  43. 43.
    Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs 5-aminosalicyclic acid in mild and moderate distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26:21–29.CrossRefPubMedGoogle Scholar
  44. 44.
    Feagon BG, Rutgeerts P, Sands B E, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy in ulcerative colitis. NEJM. 2013;369:699–710.CrossRefGoogle Scholar
  45. 45.
    Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib an oral Janus-kinas inhibitor in active ulcerative colitis. NEJM. 2012;367:616–624.CrossRefPubMedGoogle Scholar
  46. 46.
    Lobaton T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharacol Ther. 2015;42(4):441–51.CrossRefGoogle Scholar
  47. 47.
    Park SC, Jeen YT. Current emerging biologics for ulcerative colitis. Gut Liver. 2015;9(1):18–27).CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Arova Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep. (2014)
  49. 49.
    Moteno-Rincon E Serrano Ruiz FJ, Benitez Cantero JM, Vazquez Moron JM, Pilares Manrique H, Herrera Justiniano JM, Leo Camero E, et al. Prognosis of patients with ulcerative colitis in sustained remission after thiopurines withdrawal. Inflamm Bowel Dis. 2015;21(7):1564–71.CrossRefGoogle Scholar
  50. 50.
    Smith LA, Gaye DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol. 2012;18(46):6782–6789.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Lehman FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23–36.CrossRefGoogle Scholar
  52. 52.
    Schoepfer AM, Beglniger C, Stranma A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, et al. Faecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than Lichtiger Index, C reactive protein, platelets, haemoglobin and blood leucocytes. Inflamm Bowel Dis. 2013;19(2):333–4.CrossRefGoogle Scholar
  53. 53.
    Xiang J-Y, Ouyang Q, Li G-D, Xiao N-P. Clinical value of faecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008;14(1):53–57.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Guardiola J, Lobaton T, Rodriquoz-Alonso L, Riuz-Cerulla X, Avajo C, Lozyza C, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic recurrences. Clin Gastroenerol Hepatol. 2014;12(11):1865–70.CrossRefGoogle Scholar
  55. 55.
    Guy TS, Williams NN, Rosato EF. Crohn’s disease of the colon. Surg Clin North Am. 2001;81:159–168.CrossRefPubMedGoogle Scholar
  56. 56.
    Michelassi F, Block GE. Surgical management of Crohn’s disease. Adv Surg 1993;26:307–322.PubMedGoogle Scholar
  57. 57.
    Fabricius PJ, Gyde SN, Shouler P, Keighley MR, Alexander-Williams J, Allan RN. Crohn’s disease in the elderly. Gut. 1985;26(5):461–465.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Limsal D, Pardi DS. Quality of Life in ulcerative colitis. From Medscape Gastroenterology. Advamvesin Ulcerative Colitis-Vol 4.Google Scholar
  59. 59.
    Sajadinejad MS, Asgari IK, Molavi H, Kalautari M, Adibi P. Psychological issues in Inflammatory Bowel Diseases: Am Overview. Gastroenterol Res Pract. 2012;
  60. 60.
    Tabatabaelan N, Afshar H, Rooh afza HR, Daghaghadeh H, Falzi A, Sharbafchi MR, et al. Psychological stress in Iranian patients with ulcerative colitis and its relation to disease activity and quality of life. J Res Med Sci. 2015;20(6):577–84.CrossRefGoogle Scholar
  61. 61.
    Bernklev T, Jahnsen J, Henriksen M, Lygren I, Aadland E, Sauar J, et al. Relationship between sick leave, unemployment, disability and health-related quality of life in patients with inflammatory bowel disease. Infamm Bowel Dis 2006;12:402–412.CrossRefGoogle Scholar
  62. 62.
    Feagan GB, Renisch W, Rutgeerts P, Sandborn WJ, Yans S, Eisenberg D, et al. The effects of infliximab therapy on health related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007;102:798–802.Google Scholar
  63. 63.
    Rutgeerts P. Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. NEJM. 2005;353:2402–2476.CrossRefGoogle Scholar
  64. 64.
    Stierman H, Tusk C, Almer S, Strom M, Hiortswane H. Unfortunately outcome for women in study of health-related QoL, social factors and work disability in Crohn’s disease. Eur J Gastroenterol Hepatol. 2011;23:671–679.CrossRefGoogle Scholar
  65. 65.
    Stiemer H, Granno C, Bodemar G, Jarmerot G, Ockander L, Tusk C, et al. Evaluation of the Inflammatory Bowel Disorders. Question in Swedish patients with Crohn’s Disease. Scand J Gastrenterol. 2006;41:934–943.CrossRefGoogle Scholar
  66. 66.
    Han SW, McCall E, Barton JR, James P, Stein IN, Welfan MR. Predictors of quality of life: the importance of symptoms and clinical representations. Inflam Bowel Dis. 2005;11:24–34.CrossRefGoogle Scholar
  67. 67.
    Horde O, Huppertz-Hausi G, Hoivil ML, Moum B. Aust J Gastrenterol. 2014;1(4):1017.Google Scholar
  68. 68.
    Seagrove A, Rupport F, Williams J. PTU-061 Infliximab or ciclosporin: Patients’ treatment preferences and the impact of ulcerative colitis (UC) on their lives. Gut. 2014 63. A65 307263.135.CrossRefGoogle Scholar
  69. 69.
    Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MOl. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48.CrossRefPubMedGoogle Scholar
  70. 70.
    Broome U, Lofberg R, Veress B, Erikssson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22:1404.PubMedGoogle Scholar
  71. 71.
    Oldenburg B, Koningsberger JC, Van Nerge Henegouwen GP, Van Asbeck BS, Marx JJ. Aliment Pharmacol Ther 2001;15(4):429–38.CrossRefPubMedGoogle Scholar
  72. 72.
    Narita T, Akiyama M, Ohnuma H, Matsuda K. Crohn’s disease in a92-year old male. J Gastroenterol 1996;31(1):114–118.CrossRefPubMedGoogle Scholar
  73. 73.
    Greenberg GR, Feagon BG, Martin F, Sutherlsnd LR, Thomson B, Willisms N, et al. Oral budesonide for active Crohn’s disease. NEJM. 1994;337:836–84.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations